Skip to main content
Toggle navigation
Login
Search
Home
Conference Brochure
Tweets by JADPRO Live 2022
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
CE credit available
Pharmacology credit available
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
T
JL1030C
The Development of a Biomarker Database: Creating a Clinical Decision Support Tool for Oncology Nurses and Advanced Practice Providers
Clinical Posters
Favorite
JL1031C
The Development of an Advanced Practice Hematology, Oncology, and Palliative Medicine Fellowship: Improving Onboarding and Retention
Clinical Posters
Favorite
JL1035E
The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) in the United States: A Cost of Care and Budget Impact Model of Venetoclax plus Obinutuzumab Sequences for CLL Patients
Industry Encore Posters
Favorite
JL1014P
The Effectiveness of a Peer Specialist Training Program
APSHO Patient Perspective Posters
Favorite
JL1036E
The Efficacy of Enzalutamide (ENZA) Plus Androgen Deprivation Therapy (ADT) on Oligometastatic Hormone-Sensitive Prostate Cancer: Extended Post Hoc Analysis of ARCHES
Industry Encore Posters
Favorite
JL1032C
The Expanding Role of the Advanced Practice Provider in National Cancer Institute–Sponsored Trials
Clinical Posters
Favorite
JL1015P
The Psychosocial Factors Impacting African American Women Breast Cancer Survivors
APSHO Patient Perspective Posters
Favorite
JL1033C
The Surgical Oncology Advanced Practitioner Conference (2018–2021): Evaluating Educational Gaps, Needs Assessment, and Future Programs
Clinical Posters
Favorite
JL1037E
Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial
Industry Encore Posters
Favorite
JL1038E
Treatment Duration and Long-term Outcomes With Daratumumab in Transplant-ineligible Newly Diagnosed Multiple Myeloma From the Phase 3 MAIA Study
Industry Encore Posters
Favorite
JL1039E
Tumor agnostic efficacy and safety of erdafitinib in patients with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: interim analysis results
Industry Encore Posters
Favorite